Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′-deoxythymidine) in children with human immunodeficiency virus infection

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 758-763

  Kaul, S ^a   Kline, M W ^a   Church, J A ^a   Dunkle, L M ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAVUDINE;

ADULT; ARTICLE; BODY SURFACE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MIDDLE AGED; STAVUDINE;

EID: 0035115552     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.758-763.2001     Document Type: Article

References (30)

1. 2′.3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase 1 trial
2. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society - USA Panel
3. Guidelines for the use of antiretroviral agents in pediatric HIV infection
4. A formula to estimate the approximate surface area if height and weight be known
5. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex
6. Quantitative comparison of toxicity, of anticancer agents in mouse, rat, hamster, dog, monkey, and man
7. Noncompartmental analysis based on statistical moment theory
8. The importance of pharmacokinetics for pediatrics
9. Physical growth: National Cancer Center for Health Statistics percentiles
10. 2′,3′-Didehydro-2′, 3′-dideoxythymidine (D4T), an anti-HIV agent
11. Perinatal renal pharmacology
12. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex
13. High-performance liquid chromatographic determination of 2′,3′-didehydro-3′-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine
14. Specific radioimmunoassays for the measurement of stavudine in human plasma and urine
15. Clinical pharmacokinetics in infants and children: A reappraisal
16. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection
17. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection
18. Stavudine: A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection
19. Paediatric drug dosing: Body weight versus surface area
20. Lean body mass as a predictor of drug dosage: Implications for drug therapy
21. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089
22. Dose-related activity of stavudine in patients infected with human immunodeficiency virus
23. Clinical pharmacokinetics of stavudine
24. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time
25. Dosing considerations in the pediatric patient
26. Biological effects and safety of stavudine: Overview of phase I and II clinical trials
27. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, doubleblind, controlled trial
28. Dosage of drugs in infants, children, and adults